Cargando…
The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)
We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158352/ https://www.ncbi.nlm.nih.gov/pubmed/30294330 http://dx.doi.org/10.3389/fimmu.2018.02153 |
_version_ | 1783358413446578176 |
---|---|
author | Świerzko, Anna S. Michalski, Mateusz Sokołowska, Anna Nowicki, Mateusz Eppa, Łukasz Szala-Poździej, Agnieszka Mitrus, Iwona Szmigielska-Kapłon, Anna Sobczyk-Kruszelnicka, Małgorzata Michalak, Katarzyna Gołos, Aleksandra Wierzbowska, Agnieszka Giebel, Sebastian Jamroziak, Krzysztof Kowalski, Marek L. Brzezińska, Olga Thiel, Steffen Jensenius, Jens C. Kasperkiewicz, Katarzyna Cedzyński, Maciej |
author_facet | Świerzko, Anna S. Michalski, Mateusz Sokołowska, Anna Nowicki, Mateusz Eppa, Łukasz Szala-Poździej, Agnieszka Mitrus, Iwona Szmigielska-Kapłon, Anna Sobczyk-Kruszelnicka, Małgorzata Michalak, Katarzyna Gołos, Aleksandra Wierzbowska, Agnieszka Giebel, Sebastian Jamroziak, Krzysztof Kowalski, Marek L. Brzezińska, Olga Thiel, Steffen Jensenius, Jens C. Kasperkiewicz, Katarzyna Cedzyński, Maciej |
author_sort | Świerzko, Anna S. |
collection | PubMed |
description | We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3′-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery. |
format | Online Article Text |
id | pubmed-6158352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61583522018-10-05 The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) Świerzko, Anna S. Michalski, Mateusz Sokołowska, Anna Nowicki, Mateusz Eppa, Łukasz Szala-Poździej, Agnieszka Mitrus, Iwona Szmigielska-Kapłon, Anna Sobczyk-Kruszelnicka, Małgorzata Michalak, Katarzyna Gołos, Aleksandra Wierzbowska, Agnieszka Giebel, Sebastian Jamroziak, Krzysztof Kowalski, Marek L. Brzezińska, Olga Thiel, Steffen Jensenius, Jens C. Kasperkiewicz, Katarzyna Cedzyński, Maciej Front Immunol Immunology We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3′-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery. Frontiers Media S.A. 2018-09-20 /pmc/articles/PMC6158352/ /pubmed/30294330 http://dx.doi.org/10.3389/fimmu.2018.02153 Text en Copyright © 2018 Świerzko, Michalski, Sokołowska, Nowicki, Eppa, Szala-Poździej, Mitrus, Szmigielska-Kapłon, Sobczyk-Kruszelnicka, Michalak, Gołos, Wierzbowska, Giebel, Jamroziak, Kowalski, Brzezińska, Thiel, Jensenius, Kasperkiewicz and Cedzyński. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Świerzko, Anna S. Michalski, Mateusz Sokołowska, Anna Nowicki, Mateusz Eppa, Łukasz Szala-Poździej, Agnieszka Mitrus, Iwona Szmigielska-Kapłon, Anna Sobczyk-Kruszelnicka, Małgorzata Michalak, Katarzyna Gołos, Aleksandra Wierzbowska, Agnieszka Giebel, Sebastian Jamroziak, Krzysztof Kowalski, Marek L. Brzezińska, Olga Thiel, Steffen Jensenius, Jens C. Kasperkiewicz, Katarzyna Cedzyński, Maciej The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) |
title | The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) |
title_full | The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) |
title_fullStr | The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) |
title_full_unstemmed | The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) |
title_short | The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) |
title_sort | role of complement activating collectins and associated serine proteases in patients with hematological malignancies, receiving high-dose chemotherapy, and autologous hematopoietic stem cell transplantations (auto-hsct) |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158352/ https://www.ncbi.nlm.nih.gov/pubmed/30294330 http://dx.doi.org/10.3389/fimmu.2018.02153 |
work_keys_str_mv | AT swierzkoannas theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT michalskimateusz theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT sokołowskaanna theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT nowickimateusz theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT eppałukasz theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT szalapozdziejagnieszka theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT mitrusiwona theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT szmigielskakapłonanna theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT sobczykkruszelnickamałgorzata theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT michalakkatarzyna theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT gołosaleksandra theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT wierzbowskaagnieszka theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT giebelsebastian theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT jamroziakkrzysztof theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT kowalskimarekl theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT brzezinskaolga theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT thielsteffen theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT jenseniusjensc theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT kasperkiewiczkatarzyna theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT cedzynskimaciej theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT swierzkoannas roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT michalskimateusz roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT sokołowskaanna roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT nowickimateusz roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT eppałukasz roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT szalapozdziejagnieszka roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT mitrusiwona roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT szmigielskakapłonanna roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT sobczykkruszelnickamałgorzata roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT michalakkatarzyna roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT gołosaleksandra roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT wierzbowskaagnieszka roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT giebelsebastian roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT jamroziakkrzysztof roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT kowalskimarekl roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT brzezinskaolga roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT thielsteffen roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT jenseniusjensc roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT kasperkiewiczkatarzyna roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct AT cedzynskimaciej roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct |